News Hub | News Direct

Communications

Advertising Communications Graphic Design Internet Marketing Media Publishing SEO
Article thumbnail News Release

Ira J. Perlmuter, Renowned Investor and Chairman, Invests in News Direct to Fuel Growth Opportunities

News Direct

News Direct is pleased to announce a significant investment from Ira J. Perlmuter, Chief Investment Officer of IJP Family Partners. This strategic partnership underscores News Direct’s trajectory toward expansion and innovation in digital news distribution. Terms were not disclosed. Mr. Perlmuter, a recognized leader in the investment community, brings decades of business expertise and acumen to News Direct. He is a Board member of a prominent fintech bank and has served as Chairman of five companies acquired on behalf of a major family office. With an extensive track record in growing and scaling promising businesses, Mr. Perlmuter intuitively identified News Direct’s potential to become a major player in the digital news sector. IJP Family Partners serves as an outsourced Chief Investment Office (CIO) for substantial family offices, specializing in direct venture capital and private equity investments. The firm also provides expert advice on complex financing deals, portfolio company turnarounds, and restructurings. Mr. Perlmuter’s deep industry knowledge and hands-on experience in these areas make him an ideal partner to help drive News Direct’s growth. This investment will accelerate News Direct’s strategy to expand its innovative platform, which is reshaping the way businesses distribute, and consumers engage, with media content. “I see immense potential in News Direct’s business model and its ability to streamline the process of delivering news in a fast-evolving digital landscape,” said Perlmuter. “I’m excited to support their growth and help them reach new heights.” Gregg Castano, News Direct founder and CEO stated, "Ira not only brings substantial experience that will bolster News Direct's growth efforts, but more importantly he commands enormous respect throughout both the investment and business communities overall. We are tremendously proud that he has recognized our value and potential and chosen to partner with us." With Perlmuter’s collaboration, News Direct is poised to capitalize and pioneer emerging opportunities in the news dissemination market, enabling it to enhance its platform and further solidify its role as a leader and innovator in the future of media distribution. About Ira J. Perlmuter & IJP Family Partners Ira J. Perlmuter is the Chief Investment Officer of IJP Family Partners, a firm that acts as an outsourced CIO for significant family offices. IJP Family Partners advises on direct venture capital, private equity investments, and specializes in complex financing structures, turnarounds, and company restructurings. About News Direct News Direct is a technology-driven content distribution and amplification platform for PR, IR, corporate communications and marketing professionals. Our automated platform delivers a completely reimagined, modernized user experience for newswire users that has reshaped the industry landscape. Additionally, the company has expanded its offerings to include an array of technology-enhanced message amplification tools ranging from sponsored content to podcasting products, all from a single online destination. Contact Details News Direct Corp. News Direct Media Relations +1 917-698-4131 media@newsdirect.com Company Website http://www.newsdirect.com

September 25, 2024 02:26 PM Eastern Daylight Time

Article thumbnail News Release

drive21, Van Wagner Collaborate to Elevate In-Venue Branding and Fan Engagement Across College Athletics

drive21

drive21, a leader in experiential design and marketing solutions, today announced a strategic relationship with leading collegiate athletics marketing agency, Van Wagner to become a preferred experiential graphic design and implementation provider for Van Wagner. Van Wagner is recognized for its expertise in collegiate sponsorship sales and multi-media rights and will collaborate with drive21 to redefine branding strategies, drive revenue growth, and create Name, Image and Likeness (NIL) execution opportunities in the collegiate sports industry. Through this relationship, Van Wagner’s collegiate clients will be afforded advantageous pricing and access to drive21’s suite of services to provide innovative branding and design solutions across their venues; driving innovative solutions that bridge the gap between brand aspirations and reality, creating immersive environments that resonate with audiences and drive tangible business results. "This relationship represents a significant step forward in our mission to transform sports and entertainment venues into impactful environments that are also powerful marketing tools," said Warren Godridge, drive21 Founder and President. "By collaborating with Van Wagner, we can leverage our creativity and expertise to deliver a consistent brand experience across all venues, enhancing the value for brands, universities, and fans alike." “Traditional approaches often focus solely on aesthetics and overlook the potential to maximize partnership, sponsorship and NIL opportunities, leaving untapped value on the table” said John Libro, Head of Sports and Entertainment at drive21. “Working with Van Wagner College will allow us to push the boundaries of experiential design and transform collegiate athletic facilities into dynamic revenue-generating tools that engage fans and drive real business growth.” This relationship may also offer an even more comprehensive solution to collegiate clients by providing new NIL revenue streams. Through this collaboration with drive21, a portion of the facility’s expenditure can be reallocated to the universities’ NIL efforts. This allows universities to offer a more engaging experience for athletes and fans while creating dynamic environments supporting athletic performance, fan engagement and brand partnerships. "drive21’s ability to seamlessly integrate brand experiences into our facilities is a game-changer for our clients,” said Mark Donley, Chief Revenue Officer at Van Wagner College. “Through our arrangement with drive21, our university clients have an opportunity to access the expertise of drive21 to not only enhance their facilities but also ensure a consistent and high-quality experience for a variety of initiatives at an advantageous rate. It's truly a win-win-win scenario." The first major joint effort was a collaboration at Florida International University for the brand implementation of the newly named Pitbull Stadium. drive21 and Van Wagner played a key role in creating cohesive branding for the first college athletic venue named after a musician, exampling the transformative potential of experiential design and strategic branding. To learn more about the partnership, or drive21’s sports, entertainment and hospitality solutions, please visit www.drive21.com. About drive21 drive21 elevates the sports, entertainment, and hospitality industries by delivering one-of-a-kind branded venue experiences. A leader in experiential design and marketing solutions, drive21 bridges the gap between imagination and reality to deliver functional and impactful environments through design, fabrication, implementation, and holistic project management. Servicing organizations including MLB, MLS and NCAA institutions, drive21 helps its clients maximize partnership and sponsorship revenue and turns ordinary environments into extraordinary works of art. For more information, visit www.drive21.com. About Van Wagner Van Wagner is a leading sports advertising and entertainment agency with global expertise in filmed and live entertainment, sponsorship sales, multi-media rights, and aerial advertising. Van Wagner creates, advises, and sells for world-class teams, leagues, brands, and properties. An innovator in the sports and media business, Van Wagner is a global leader in high-impact broadcast visible signage throughout the MLB, NBA, NCAA, and international soccer, sponsorships sales, college multi-media rights, and in-venue content production at the world’s biggest sporting events. For more information, visit www.vanwagner.com. Contact Details Hot Paper Lantern Jackson Gaskins jgaskins@hotpaperlantern.com Company Website https://drive21.com

September 25, 2024 08:00 AM Eastern Daylight Time

Article thumbnail News Release

Taglich Brothers Maintains Speculative Buy Rating On Cosmos Health With $4 Price Target, Highlighting Potential Valuation Upside

Marel Corporation Ltd

By Marel Corp Cosmos Health ($COSM or 'Cosmos') is a global healthcare group that remains significantly undervalued by the market, despite strong execution and broad diversification across multiple sectors. The company boasts an innovative R&D division that leverages AI-driven drug repurposing, along with ownership of proprietary pharmaceutical and nutraceutical brands like Sky Premium Life. As a vertically integrated manufacturer of medicines, Cosmos is strategically positioned within the healthcare industry. Additionally, its logistics arm, CosmoFarm, distributes healthcare products to over 1,000 pharmacies, while its telehealth platform further strengthens the company’s presence in the evolving healthcare landscape. Despite the company generating nearly $60 million in annual revenue—expected to grow to $155.80 million by 2027, according to the company’s guidance for the 2024-2027 period—its market cap remains depressed at just around $20 million. The share price has dropped significantly over the past couple of years, despite notable progress on multiple fronts. Based on the guidance provided issued by the company, it expects to be highly profitable in the coming years, with EBITDA projected to reach nearly $30 million by 2027. Specifically, the company issued the following guidance: The anticipated achievements are expected to result from a combination of strategic initiatives, including a focus on higher-margin business segments, operational synergies, and enhanced cost efficiency. As highlighted by the company, the following key priorities could drive this growth: Expansion of Sky Premium Life's global footprint and product range, introducing new formulas, therapeutic areas, and customized offerings. This will be supported by strategic partnerships with exclusive distributors and digital channels. Global launch of C-Sept and C-Scrub, both of which possess significant market potential and face limited competition. Production is being scaled up, with additional products in the development pipeline. Expansion of generic pharmaceuticals across the EU and international markets, with a focus on advanced generics and innovative OTC products. Optimization of Contract Manufacturing Organization (CMO) operations, prioritizing high-demand medicines and competitive pricing strategies. Progress toward World Medical Organization (WMO) patent approval and completion of clinical trials for the CCX obesity pill by 2025, with commercialization anticipated in 2026. Driving organic growth by integrating the pharmacy distribution network to enhance efficiency and scalability. Corporate reorganization efforts, focusing on cost-cutting initiatives and optimizing asset and resource utilization through the integration of business units. These initiatives aim to propel the company forward while delivering sustained profitability and operational growth. Sharing the company’s optimistic outlook, Taglich Brothers recently published an updated research report on the company's common stock. Taglich maintains a Speculative Buy rating with a $4 price target, implying a nearly four-fold increase in the share price over the next 12 months. Taglich estimates that the company’s valuation should improve alongside revenue growth, which is expected to translate into operating profits and positive cash flow. Currently, Cosmos's price-to-sales multiple (0.3x) significantly trails the sector average of 2.4x for comparable companies in medical distribution and drug manufacturing, indicating a potential catch-up opportunity. Moving forward, investors are likely to assign a valuation multiple closer to industry norms. Even with a conservative approach, applying a lower-than-average price-to-sales multiple of 1.4x to the 2025 sales per share forecast of $3.86 supports the $4 price target, accounting for execution risks and potential warrant dilution. Recently, the company has rapidly secured distribution agreements for its proprietary Sky Premium Life brand across the GCC—including Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates—as well as in European markets like Slovakia, Hungary, Poland, and Czechia. It has even signed exclusivity agreements to distribute real-time mpox (formerly monkeypox) PCR tests as far as India. In summary, Cosmos Health is a company worth monitoring as it works to position itself for potential alignment with industry peers. Featured image sourced from Shutterstock Marel Corp is an investor in stocks, employing diverse strategies across sectors and company sizes. This post was authored by an external contributor and does not represent Benzinga's opinions and has not been edited for content. This contains sponsored content and is for informational purposes only and not intended to be investing advice. Contact Details BDG Communications +44 20 7097 1653 info@bdgcommunications.com

September 24, 2024 12:00 PM Eastern Daylight Time

Image
Article thumbnail News Release

AI Unpacks Generational Stereotypes, Highlighting Key Differences, but Beer Bridges the Gap

AIport

What happens when you ask generative AI models to depict Baby Boomers, Gen X, Millennials, and Gen Z? You might expect tech-challenged Boomers and avocado-loving Millennials. But what you get is far more interesting and in some cases, unexpected. A joint research project conducted by AIport and Turing Post last month analyzed over 1200 AI-generated images across four different models—Stable Diffusion, Midjourney, YandexART, and ERNIE-ViLG. The findings have revealed both familiar stereotypes and surprising quirks about how AI perceives these generations. Sad Boomers, Happy Zoomers? Contrary to the carefree Boomer stereotype, AI models like Midjourney depict Baby Boomers as introspective, or even somber, often bundled up and gazing wistfully into the distance—a reflection, perhaps, of their disillusionment with the unfulfilled ideals of the 1960s cultural revolution. However, the ERNIE-ViLG model, likely trained on datasets with a more collectivist cultural slant, shows 93% of Boomers smiling. This fascinating contrast underscores the cultural differences embedded in different AI models. Meanwhile, Gen Z’s images are vibrant and diverse, reflecting their reputation as a generation that embraces individuality, inclusivity, and self-expression. The AI-generated images depict Zoomers in colorful, highly detailed scenarios, making them the most visually distinct generation in the study. Generations Through the AI Lens The research explored how generations are portrayed in five key aspects of life: identity, relationships, work, lifestyle, and consumer habits. The AI models revealed consistent patterns and stereotypes; for example, males predominated in the depictions of Boomers and Gen Xers across all four models, while many images of Millennials and Zoomers showed greater diversity and more female representation. Surprisingly, Gen X appears to be the least well-understood generation by AI, characterized by fewer defining features compared to all other generations, likely due to the limited amount of training data available. The one stereotypical Gen X leitmotif that AI consistently identifies is their fondness for flannel shirts—an unmistakable symbol of the 1990s grunge scene worn by Gen Xers who were rebellious teenagers and young adults during that era. As for one (un)expected commonality… It’s beer. Whether they’re Millennials job-hopping or Boomers reminiscing about the good old days, AI consistently showed beer in 34% of the produced images across all generations. Prompt Engineering and AI Insights The prompts for this research were carefully crafted to avoid bias, using neutral phrases like "A Millennial at work" or "A Boomer relaxing." The results offer a telling look at how generative AI models mirror societal stereotypes, often shaped by the data they're trained on. These findings open the door to deeper discussions on how AI reflects, and sometimes distorts, cultural narratives. "Whether we think we can learn about generations from these images depends upon how confident we feel that the training data that went in is an accurate image of the self identity of a group,” explains Senior Engineer and Sociologist Stephanie Kirmer, who analyzed the findings. “For the younger sets, I don’t think we can know how much of it is media representation created by people outside the group versus how much is selfie-style personal expression. Some of what we’re getting, especially for the older groups who don’t contribute as much self-generated visual media online, is perceptions of that group from advertising and media, which we know has inherent flaws." About the Study The study examined the outputs of four globally recognized generative AI models, each with distinct aesthetic and cultural nuances, providing a comprehensive look at how each generation is portrayed visually. The selected models included Stable Diffusion, Midjourney, YandexART, and ERNIE-ViLG, offering diverse perspectives from different regions across the globe. Conclusion Whether confirming or contradicting societal stereotypes, AI-generated images provide a fascinating snapshot of how technology interprets generational differences. The fact that beer remains a unifying theme across all four models shows that, no matter our age, some things—like enjoying a cold one—transcend generational divides. To learn more about the project, visit https://www.aigenerations.tech/. Hero images for the media: Google Drive Link About AIport AIport is an emerging community of AI/ML enthusiasts and practitioners with a goal of providing a truly global view of the AI/ML/DS landscape. https://www.blog.aiport.tech/ About Turing Post Turing Post is everything you need to make smarter decisions about AI. https://www.turingpost.com/ Contact Details Nick Leighton nick.leighton@nettresultsllc.com Company Website https://www.aigenerations.tech/

September 23, 2024 10:00 AM Eastern Daylight Time

Article thumbnail News Release

BestGrowthStocks.Com Issues Comprehensive Analysis of Globalstar Inc’s Strategic Partnerships and Growth Drivers

Global Star Inc. (GSAT)

NEW YORK, NY / NewsDirect / September 23rd, 2024 / Best Growth Stocks, a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing exclusive ai-assisted research recently issued a comprehensive analysis of Globalstar Inc. a satellite and terrestrial connectivity services as an international telecom infrastructure provider. Globalstar Inc. (NYSE: GSAT) has garnered significant investor attention following recently reported revenue growth. Best Growth Stock's full report analyzes Globalstar’s operations, competitive advantages and disadvantages, potential catalysts, growth drivers, strategic partnerships, financials, key customers, management evaluation, share structure, chart, support and resistance levels, and more. Access this full analysis free here: https://bestgrowthstocks.com/access-gsat-analysis/ About Globalstar Globalstar empowers its customers to connect, transmit, and communicate in smarter ways – easily, quickly, securely, and affordably – offering reliable satellite and terrestrial connectivity services as an international telecom infrastructure provider. The Company’s LEO satellite constellation assures secure data transmission for connecting and protecting assets, transmitting critical operational data, and saving lives for consumers, businesses, and government agencies across the globe. Globalstar’s terrestrial spectrum, Band 53, and its 5G variant, n53, offer carriers, cable companies, and system integrators a versatile, fully licensed channel for private networks with a growing ecosystem to improve customer wireless connectivity, while Globalstar’s XCOM RAN product offers significant capacity gains in dense wireless deployments. In addition to SPOT GPS messengers, Globalstar offers next-generation IoT hardware and software products for efficiently tracking and monitoring assets, processing smart data at the edge, and managing analytics with cloud-based telematics solutions to drive safety, productivity, and profitability. For more information, visit www.globalstar.com. About Best Growth Stocks Best Growth Stocks is a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing our exclusive ai-assisted research. BGS is also a financial news provider, focused on giving investors direct access to CEOs of promising, publicly-traded companies, and market experts. Our CEO interviews aim to answer the questions that rest on the minds of current and future shareholders. This is not to be construed as financial advice. Please consult with a licensed financial advisor before making any investment decisions. Media Contact Best Growth Stocks Senior Editor: Steve Macalbry Editor@BestGrowthStocks.Com SOURCE: BestGrowthStocks.Com Contact Details Media Source LLC Steve Macalbry +1 989-274-7778 editor@bestgrowthstocks.com Company Website https://bestgrowthstocks.com/

September 23, 2024 07:00 AM Eastern Daylight Time

Article thumbnail News Release

Siti Non AAMS - Migliori Siti Casino & Scommesse 2024

AM Europe

Sono sempre di più gli utenti italiani che scelgono di scommettere sui cosiddetti siti non AAMS. Questi concessionari operano con licenze internazionali e garanwtiscono l’accesso a generosi bonus senza deposito, a più metodi di pagamento, e a dei giochi che sui siti AAMS solitamente non si trovano. Chiunque sia alla ricerca di siti di scommesse legali in Italia seppur al di fuori della normativa AAMS, in questa guida andremo proprio a fornire una panoramica sui migliori operatori di questo genere. Tabe di Siti Non AAMS & Casino non AAMS Perché gli Italiani Scelgono i Bookmaker Non AAMS Gli italiani scelgono i siti non AAMS per tante motivazioni differenti, che si rifanno principalmente a ciò che riguarda le promozioni, alla selezione di giochi e prodotti disponibili e alla struttura di diverse funzionalità delle piattaforme stesse. Bonus più generosi Meno restrizioni Ampia varietà giochi Programmi VIP esclusivi Tornei giornalieri Lista dei Migliori Siti non AAMS Panoramica Di seguito, proponiamo una lista di quelli che a nostro parere sono i migliori siti non AAMS, con tanto di descrizione dei punti di forza di ciascuno: HappySlots: Questo casinò rappresenta il paradiso per gli amanti delle slot machine, in quanto propone una selezione capace di abbracciare migliaia di titoli differenti. I giocatori possono quindi esplorare una miriade di temi e funzionalità all’interno di HappySlots, portale capace di far provare sempre qualcosa di nuovo ai propri utenti, soprattutto grazie alle frequenti aggiunte di titoli originali. WildTokyo: Perfetto per chi cerca dell’adrenalina su base quotidiana, questo casinò online si ditingue per offrire promozioni e gare con premi che vengono assegnati ogni giorno; infatti, all’interno di questo portale vengono proposte giornalmente nuove sfide e bonus che rendono l’esperienza di gioco sempre dinamica e ricca di opportunità da cogliere per usufruire di ricompense extra. ProntoBet: Con un palinsesto sportivo che non ha nulla da invidiare ai principali bookies mondiali, ProntoBet è sicuramente il sito ideale per gli appassionati di scommesse sportive. L’offerta di ProntoBet copre tutti gli eventi sportivi globali e consente agli utenti di scommettere su una vasta gamma di discipline con quote molto competitive. Winsane: Questo portale è rinomato per il suo eccellente e ben strutturato programma fedeltà; grazie a quest’ultimo, i giocatori più assidui possono beneficiare di bonus esclusivi e trattamenti VIP personalizzati che vanno a premiare la loro fedeltà con vantaggi unici e premi assegnati su misura. Cashwin: Con un’offerta che prevede la fruizione costante di nuove promozioni per nuovi iscritti e utenti già registrati, Cashwin è senza dubbio l’ideale per chi ama passare il proprio tempo nel tentativo di sfruttare al meglio dei bonus vantaggiosi. Le promozioni disponibili sono generose e spesso sono pensate per incrementare percentualmente i fondi di gioco che vengono depositati in maniera davvero significativa. Quickwin: La punta di diamante di Quickwin è costituita dalla lounge dedicata al casinò live, in cui è possibile trovare tutti i giochi con croupier dal vivo. Gli amanti dell’interattività e della dinamicità del casinò potranno trovare un’ampia selezione di titoli in grado di ricreare fedelmente l’ambiente di un casinò reale, soprattutto grazie alla qualità dei giochi offerti. Perchè gli Italiani scelgono i Siti non AAMS Come detto in precedenza, i siti non AAMS stanno rapidamente guadagnando popolarità tra gli scommettitori italiani, poiché offrono una serie di vantaggi che superano quelli dei bookmaker regolamentati dall’AAMS. Grazie a bonus mediamente più generosi, metodi di pagamento che includono anche le criptovalute e selezioni di giochi più estese, questi siti stanno diventando sempre più gettonati. Qui sotto abbiamo preparato un elenco di motivi, dettagliati uno per uno, per i quali gli utenti si stanno spostando sempre più verso queste alternative ai casinò online tradizionali. Bonus e promozioni: I siti non AAMS propongono bonus più generosi rispetto alle controparti regolate dall’AAMS e spesso assicurano anche giri gratuiti e bonus senza deposito che sono sempre molto graditi a tutti gli utenti; Metodi di pagamento: I siti non AAMS supportano molti altri metodi di pagamento come le criptovalute oltre alle opzioni più classiche come possono essere le carte di credito e i portafogli elettronici; Selezione di giochi: Offrendo una gamma di giochi da casinò tendenzialmente più ampia rispetto ai casinò normali, i siti non AAMS si fanno preferire per la maggiore varietà a cui gli utenti possono avere accesso; Licenze e sicurezza: Pur non regolamentati dall'AAMS, i siti non AAMS possiedono licenze internazionali, assicurando elevati standard di sicurezza e protezione per dati personali e transazioni finanziarie. Supporto clienti: Il supporto multilingue dei siti non AAMS, solitamente disponibile tramite chat live, email e telefono, garantisce assistenza immediata che permette di risolvere ogni tipologia di problema efficientemente. Pro e Contro dei Siti Non AAMS Pro: Ampia gamma di bonus, varietà di giochi, flessibilità nei pagamenti e meno restrizioni. Contro: Il servizio clienti di queste piattaforme a volte potrebbe tardare più del dovuto nelle risposte. Cos'è un sito di scommesse sportive non AAMS? Un sito di scommesse sportive non AAMS è una piattaforma che opera senza la licenza italiana rilasciata dall’Agenzia delle Dogane e dei Monopoli, ma che possiede comunque una attestazione internazionale. Questi siti consentono agli utenti di piazzare scommesse sempre sulla maggioranza degli eventi sportivi internazionali, ma offrendo un numero di mercati che generalmente va oltre a quello proposto dai siti AAMS; infatti, come abbiamo già sottolineato, le piattaforme non AAMS sono note per avere regole meno rigide sotto tutti i punti di vista, il che significa spesso limiti di scommessa più alti, bonus più generosi e metodi di pagamento più variegati. Come registrarsi nei Siti non AAMS Registrarsi su un sito di scommesse non AAMS spesso passa da un processo più rapido rispetto a quello che si deve affrontare all’interno dei casinò tradizionali, grazie a procedure meno rigide in termini di raccolta dati. In molti casi, i siti non AAMS consentono di registrarsi con metodi alternativi come Google o Apple ID, in modo da abbattere le tempistiche necessarie per creare un nuovo conto di gioco. Inoltre, al posto della classica procedura di convalida obbligatoria dei documenti entro 30 giorni, come richiesto dai casinò AAMS per evitare la sospensione del conto, i siti non AAMS adottano procedure di Know Your Customer (KYC) meno invasive; questo significa che, anche se il processo di KYC non viene portato a termine correttamente, l'utente può comunque accedere liberamente a tutte le funzionalità del casinò ad eccezione dei prelievi, che vengono resi disponibili solo dopo aver completato questa procedura. Visitare il sito scelto: La prima cosa da fare è recarsi nella homepage del sito di scommesse non AAMS; Cliccare su "Registrati": Successivamente, bisogna cliccare sul pulsante di registrazione che è solitamente piazzato in alto a destra nella pagina principale del sito; Compilare il modulo: Arrivati qui, toccherà all’inserimento dei propri dati personali, come nome, cognome, indirizzo email e numero di telefono; alcuni siti potrebbero richiedere anche la creazione di un nome utente; Verificare l'account: Infine, bisognerà inviare una copia dei documenti richiesti per la verifica dell'identità, passaggio fondamentale per sbloccare la possibilità di effettuare dei prelievi. Giochi da casinò disponibili I siti non AAMS sono particolarmente indicati per gli amanti dei giochi del casinò, in quanto spesso e volentieri sono presenti decine di alternative per ciascuna delle categorie di giochi principali. Giochi da tavolo I giochi da tavolo includono grandi classici come blackjack e baccarat, con molte varianti alternative utili per adattarsi a diversi stili di gioco. Slot Dalle slot tradizionali alle video slot con grafiche particolareggiate, queste piattaforme offrono anche titoli con jackpot progressivi capaci di portare a vincite significative. Casinò live Il casinò live offre un'esperienza estremamente realistica con un croupier reale e include tsvoli di giochi come roulette, blackjack e poker dal vivo. Blackjack Il blackjack è disponibile sia offline live, permettendo ai giocatori di scegliere se giocare a delle partite automatizzate o in diretta con dei croupier. Roulette Le varie versioni di roulette includono quella europea, quella americana e quella francese, con sempre diverse opzioni di scommessa disponibili sia virtualmente che live. I casinò non AAMS sono legali in Italia? Sì, i siti non AAMS sono legali anche in Italia nonostante operino tramite delle licenze internazionali, come possono essere quelle rilasciate da Malta o Curaçao, piuttosto che con licenze AAMS. Questo significa che, pur non essendo regolamentati direttamente dal governo italiano, questi portali possono comunque offrire servizi di scommessa e gioco d'azzardo ai residenti in Italia senza alcuna implicazione a livello legale. Per chiudere, pensiamo sia importante ricordare che, nonostante sia sempre garantito che questi casinò operano legalmente, i giocatori dovrebbero sempre verificare la licenza sotto cui il sito opera per assicurarsi che siano protetti e che i loro fondi siano al sicuro. Metodi di deposito e prelievo Spesso, i siti di scommesse non AAMS danno la possibilità agli utenti di prelevare e versare denaro tramite decine di metodi di pagamenti differenti da quelli solitamente messi a disposizione dai concessionari. Queste piattaforme sono ben consapevoli dell'importanza di effettuare transazioni rapide e sicure, e per questo motivo mettono a disposizione diverse opzioni per soddisfare le esigenze di un pubblico internazionale; che si tratti di carte di credito, portafogli elettronici o bonifici bancari, ogni giocatore può trovare il metodo di pagamento che meglio si adatta alle proprie preferenze e necessità. L'inclusione delle criptovalute in alcuni di questi siti rappresenta un ulteriore passo avanti verso la modernizzazione delle operazioni finanziarie, in modo da garantire non solo velocità, ma anche un alto livello di anonimato e sicurezza. Vediamo ora nel dettaglio quali sono le opzioni di pagamento più comuni disponibili sui siti di scommesse non AAMS. Visa: La carte di credito Visa costituiscono uno dei metodi di pagamento più popolari e diffusi nei siti di scommesse AAMS e non. Visa garantisce che le transazioni siano sempre protette da tecnologie avanzate di crittografia, in modo da ridurre al minimo il rischio di frodi. Inoltre, la velocità delle operazioni consente ai giocatori di avere i fondi disponibili immediatamente per scommettere; tuttavia, è bene ricordare che per alcuni siti potrebbero essere applicate commissioni e che i tempi di prelievo potrebbero variare sulla base delle condizioni imposte dal concessionario. Mastercard: Mastercard è un'altra carta di credito largamente accettata all’interno dei siti non AAMS. Anche questa opzione prevede la stessa rapidità nelle transazioni e la protezione dalle frodi grazie all’utilizzo di sistemi di sicurezza piuttosto avanzati; come per Visa, anche con Mastercard si possono incontrare tempi di attesa per i prelievi che variano a seconda del sito, ma la trasparenza delle commissioni e la velocità nelle operazioni hanno reso questo metodo una scelta molto popolare; Paypal: Paypal è uno dei portafogli elettronici più utilizzati nei siti non AAMS e non. La sua popolarità deriva dalla facilità d'uso della sua interfaccia e dalla velocità di evasione delle transazioni, i cui processi permettono ai giocatori di effettuare depositi e prelievi in pochi click e secondi. Inoltre, ricordiamo che Paypal è sinonimo di un ulteriore livello di sicurezza, in quanto funge da intermediario tra il conto bancario del giocatore e il sito senza che le informazioni sensibili vengano mai condivise direttamente con il casinò. Neteller: Neteller è uno dei portafogli elettronici preferiti dai giocatori che utilizzano i siti non AAMS per via della sua alta velocità e semplicità. Le transazioni con Neteller sono quasi istantanee e permettono di trasferire fondi rapidamente, sia per i depositi che per i prelievi. Inoltre, questo portafoglio elettronico assicura un elevato livello di sicurezza, grazie a sistemi di crittografia avanzati. Bonifico bancario: Operare tramite il bonifico bancario rimane un metodo tradizionale, utilizzato soprattutto da chi preferisce trasferire fondi direttamente dal proprio conto corrente senza l'intermediazione di carte o portafogli elettronici. Anche se questo metodo offre un’elevata sicurezza, grazie al sistema bancario regolamentato, i tempi di elaborazione possono essere più lunghi rispetto ad altre opzioni, richiedendo fino a 5 giorni lavorativi per il completamento di qualsiasi tipo di giocata. Bonus e Promozioni sui Siti non AAMS Uno dei motivi principali per cui molti giocatori scelgono i siti non AAMS sta nella generosità e varietà dei bonus e delle promozioni disponibili. Questi casinò offrono promozioni molto più competitive rispetto ai siti regolamentati dall’AAMS, con cifre spesso superiori, bonus senza deposito, e programmi fedeltà più vantaggiosi. Molti siti non AAMS propongono anche promo come i cashback settimanali o mensili, che permettono di vedersi restituita una percentuale delle perdite subite per via delle giocate non vincenti. Infine, i tornei giornalieri e le race con premi extra sono una caratteristica comune, capace di attirare i giocatori con promozioni dinamiche e costanti. Ecco alcune delle offerte più comuni: Free Spins: Si tratta di gratuiti offerti su slot selezionate, ideali per provare nuovi giochi senza rischiare il proprio denaro. Bonus senza deposito: Uno dei preferiti dai nuovi iscritti, permette di iniziare a giocare senza dover effettuare un deposito con i propri soldi. Wagering: Condizioni di giocata che talvolta sono più favorevoli rispetto ai siti AAMS, consentendo di soddisfare i requisiti di scommessa in modo più semplice. Cashback: Alcuni casinò non AAMS offrono un ritorno percentuale sulle perdite nette, in modo da garantire ai giocatori un piccolo rimborso. Software disponibile sui bookmaker non AAMS I siti non AAMS collaborano con alcuni dei migliori provider di software nel settore del gioco d’azzardo allo scopo di garantire un’esperienza fluida in ogni momento. Questi provider sono responsabili dello sviluppo di giochi equi, con funzionalità innovative e grafiche di alta qualità. Curacao I siti di scommesse con licenza rilasciata dalla giurisdizione di Curacao collaborano con alcuni dei più celebri provider di software della scena, tutto per offrire giochi godibili ed equi. NetEnt Betsoft Evolution Gaming Pragmatic Play Yggdrasil MGA Anche i siti regolati dalla Malta Gaming Authority (MGA) collaborano con fornitori di software leader del settore per assicurare che l’esperienza di gioco sia la migliore possibile. Microgaming Play’n GO Quickspin Thunderkick Evolution Gaming Le Nostre Conclusioni In conclusione, ci siamo convinti del fatto che i siti non AAMS rappresentano senza dubbio un’alternativa valida per chi cerca maggiore libertà, promozioni più generose e un elenco di giochi più fornito rispetto alle disponibilità dei casinò tradizionali. Anche se non regolamentati direttamente dall’AAMS, molti di questi siti operano con licenze riconosciute a livello internazionale che garantiscono inconfutabilmente un livello di sicurezza molto elevato. Tuttavia, ricordiamo che è fondamentale che i giocatori siano consapevoli dei possibili rischi che possono correre e che scelgano piattaforme con una buona reputazione e licenze affidabili come quelle di cui abbiamo parlato all’interno di questa stessa panoramica. Domande Frequenti (FAQ) È sicuro giocare all’interno di un sito non AAMS? Sì, i siti non AAMS che possiedono licenze internazionali come quelle di Curaçao o Malta offrono livelli di sicurezza paragonabili a quelli AAMS. Quali bonus posso ottenere sui siti non AAMS? I siti non AAMS offrono bonus senza deposito, giri gratuiti, cashback e promozioni personalizzate, solitamente in misura maggiore rispetto ai bookmaker AAMS. Posso prelevare le vincite dai siti non AAMS? Sì, i siti non AAMS permettono prelievi tramite carte di credito, portafogli elettronici come Neteller e PayPal, bonifici bancari, criptovalute e non solo. I siti non AAMS sono legali in Italia? Sì, i siti non AAMS sono legali per i giocatori italiani; tuttavia, essendo regolamentati da autorità internazionali, operano al di fuori del sistema di licenze italiano. Contact Details Berardo Bianchi +39 035 0445 9954 Berardo@itsitinonaams.com Company Website https://www.casinolistingonline.com/

September 20, 2024 04:09 AM Eastern Daylight Time

Image
Article thumbnail News Release

TRUST RELATIONS NAMED A FINALIST FOR WOMEN-RUN WORKPLACE OF THE YEAR IN THE 2024 STEVIE® AWARDS FOR WOMEN IN BUSINESS

Trust Relations

Trust Relations has been named a finalist in the 21st annual Stevie Awards for Women in Business for the third consecutive year. The agency was nominated in the category of “Women-Run Workplace of the Year - More than 10 Employees” for cultivating both a considerate company culture and outstanding performance during the 2024 award cycle. Hailed as the world’s premier business awards, The Stevie Awards for Women in Business honor the world’s leading women executives, entrepreneurs, employees and the companies they run. “Trust Relations was born from my desire to create the workplace that I’d always wished existed. It’s so rewarding to not only see that dream come true, but also to be recognized for the considerate culture we have successfully created,” said Trust Relations CEO & Founder April White. “There are so many amazing women in leadership roles now at Trust Relations, who all strive to make this agency the most respectful and collaborative place I have ever worked.” White previously won a Silver Award in the category of “Maverick of the Year” in 2023 and a Gold Award for “Most Innovative Woman of the Year” in 2022, each in the Advertising, Marketing & Public Relations subcategory. White’s previous awards have exemplified her longstanding efforts to improve agency culture and operations, and the communications industry at large, as well as her mission to replace public relations with “trust relations.” This year’s award recognizes the impact a trust-focused approach can have within the workplace, with Trust Relations’ exceptional focus on cultivating a “Considerate Culture” by emphasizing work-life balance, employee wellness, mentorship, and career excellence. Entries were evaluated from the average scores provided by six juries, composed of more than 200 business professionals around the world. Final announcement of Gold, Silver, and Bronze Stevie Award placements will be revealed at the 21st annual awards dinner and presentations. The gala will be held in New York on November 8, 2024. “I couldn’t be more proud of what the women leaders at Trust Relations have accomplished, and their continuous dedication to showing the world what a culture that puts people first can look like,” White said. “The honor of this prestigious award is just one example of what we can achieve together, with our shared commitment to team spirit, work-life balance, and kindness. We hope it will inspire other companies to take a similar approach, in an effort to create the considerate workplaces of the future.” Details about the Stevie Awards for Women in Business and the list of Finalists in all categories are available at www.StevieAwards.com/Women. For more information about Trust Relations, visit www.trustrelations.agency. About Trust Relations Founded in 2019 by award-winning PR veteran-turned-disruptor and official TEDx speaker April White, Trust Relations is the first fully remote strategic communications and integrated marketing agency. It offers access to the best PR and marketing professionals nationwide across every industry. The agency’s proprietary model provides clients with unparalleled transparency, helps align its storytelling and “story-doing,” and unlocks exceptional value for businesses. It also empowers Trust Relations to scale alongside clients by providing everything from basic support to creative activations that maximize brand exposure. The agency’s mission is to replace public relations with “trust relations” by discovering and championing every brand’s authentic truth. Trust Relations’ unique approach and comprehensive suite of services empowers organizations to achieve alignment between what they want people to think about their brands and how they can “show” as well as “tell” stories that demonstrate those proof points. For more information, visit https://www.trustrelations.agency. About The Stevie Awards Stevie Awards are conferred in eight programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, The American Business Awards®, The International Business Awards®, the Middle East & North Africa Stevie Awards, the Stevie Awards for Women in Business, the Stevie Awards for Great Employers, and the Stevie Awards for Sales & Customer Service. A ninth program, the Stevie Awards for Technology Excellence, will debut in 2024. Stevie Awards competitions receive more than 12,000 nominations each year from organizations in more than 70 nations. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at www.StevieAwards.com. Trust Relations, founded in 2019, is a virtual strategic communications firm that creates nimble and proactive “dream teams” for clients through a national network of the industry’s best and brightest practitioners. "Trust Relations" is a term coined by President and Founder April White to describe a new approach to strategic communications focused on communicating clients' authentic actions, value and goodwill. In technology, trust relationships are an administration and communication link between two domains. In communications, they are a bond of mutual respect between a brand and the people it serves. The firm excels at identifying inspiring ways for clients to show their brand value by identifying supportive proof points and ideating creative activations that demonstrate their unique story and value proposition. For more information, visit https://www.trustrelations.agency/. Contact Details April White +1 323-216-8589 april@trustrelations.agency Company Website https://trustrelations.agency/

September 19, 2024 10:00 AM Eastern Daylight Time

Article thumbnail News Release

Brand Engagement Network Brings AI Assistants To Medical Coaching And The $6.7 Billion Concierge Medicine Market Following The Expansion Of Its Board

Benzinga

By Anthony Termini, Benzinga The world of healthcare is rapidly changing, with holistic, accessible care as a key element. In the aftermath of a global pandemic, many patients are demanding a wider range of services that meet a broader range of needs. We may even potentially be entering a golden age of healthcare where patients are being prioritized more than ever, and technology is rapidly advancing to assist physicians in achieving these goals. Brand Engagement Network (BEN) (NASDAQ: BNAI), an artificial intelligence (AI) company, aims to enhance support in this radically expanding industry. The company is an emerging provider of personalized patient engagement. It uses AI to power technology that can see, hear and understand the input it receives from a patient. Using human-like avatars as the interface, BEN says its HIPAA-compliant technology can support highly specific patient requests and can remember, analyze, speak and gesture in a similar way that a person would in a human-to-human interaction. The company’s AI assistants can provide insights about preventative medicine and healthcare options based on a patient’s insurance and health plan while also protecting sensitive medical information. These human-modeled AI assistants are also designed to help augment health and wellness coaching. BEN’s AI Assistants Are Filling Gaps In The Healthcare Industry In August 2024, the company entered an agreement with Members Only Health, a full-service concierge healthcare company. The members-only agreement sets up the development of an AI assistant to serve a number of patient needs. These may include the 24/7/365 availability of a personal concierge to navigate and coordinate the global network Members Only Health (MOH) maintains across providers, health plans and preventative medicine data. Now, MOH expects to have the ability to scale its business much faster and more efficiently by deploying AI assistants to support its growing client base. Nicholas Argento, CEO of Members Only Health says that patients who use healthcare concierge services benefit from professional care around the clock. He adds that AI technology like BEN’s can help ensure that patients “have access to up-to-date healthcare information and the most convenient options for treatment.” The concierge medicine market in the U.S. reached $6.7 billion in 2023. The market is expected to grow annually by nearly 10.4% through 2030. Not to mention, concierge services’ focus on accessibility will be even more important in the coming decades, as our population continues to age; by 2054, 84 million adults ages 65 and older will make up an estimated 23% of the population. BEN also entered into an agreement with INTERVENT International, a key player in the health coaching industry. The agreement with INTERVENT is intended to incorporate human-modeled AI assistants into INTERVENT’s scientifically proven health coaching programs. The goal is to scale a cost-effective, in-depth and conversational support system for both professional health coaches and patient participants. Led by physicians, INTERVENT is a high-tech/high-touch health management company. It delivers evidence-based behavior change and entity-wide or population-based health and wellness coaching. The agreement with BEN is aimed at helping INTERVENT train coaches faster and serve more program participants at a lower cost than would be possible with human interaction alone. INTERVENT’s CEO, Neil Gordon, MD, PhD, MPH, believes AI-driven technology will benefit healthcare providers and patients. He says that “AI will not replace appropriately trained health coaches, but appropriately trained health coaches who leverage purpose-built AI and other technologies are likely to replace those who do not.” How BEN Is Ensuring It Has A Strong Team To Herald In This New Age Of Healthcare And Technology “AI technology offers an incredible opportunity to vastly improve patient outcomes,” said Richard Isaacs, MD, FACS, Dean of the College of Medicine and Professor of otolaryngology at California Northstate University. Isaacs has an intimate understanding of the intersection of technology innovation and medicine and in 2021 was regarded by Modern Healthcare as one of the 100 Most Influential People in Healthcare. Isaacs is a recent addition to BEN’s Board of Directors. At the time of his appointment, he said that he has “always pursued the realization of what is possible in healthcare with new technologies” and that he looks “forward to helping guide BEN’s development of new applications … in the industry.” With the increasing adoption of AI technologies, BEN’s commitment to creating a team of innovators and experts can help set it apart from competitors. Issacs has a long history of embracing new technologies to benefit physicians and patients alike. While he was the chief physician at South Sacramento Medical Center, Issacs led the development and implementation of Kaiser Permanente’s electronic health record system. Under his direction, the facility first began using smartphone applications to help enhance personalized care and improve overall patient experiences. At the company’s core, it is interested in using its proprietary technology to advance industries that require support. It does not seem to be interested in the model of AI for the sake of AI, but rather in developing a robust AI product and connecting with partners to see how it can best assist in bringing evolution to industries in flux. “Improving patient experiences and healthcare outcomes starts with elevating the education and training of healthcare professionals, and enhancing access to healthcare,” said Paul Chang, CEO of BEN. “Supplementing training programs, health coaching (digital and otherwise), and patient engagement with AI technology helps to address significant resource and labor gaps in the healthcare industry while empowering professionals and patients to make informed decisions for optimal health.” Brand Engagement Network believes these agreements will help drive the development of healthcare AI assistants to augment and automate business processes ranging from professional health coaching to patient engagement. The collaborations are expected to help people access specialized healthcare, which may improve patient outcomes. To see more ways BEN is empowering the healthcare industry – as well as other important business sectors worldwide – visit the company’s website. Featured photo by Bermix Studio on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 19, 2024 08:35 AM Eastern Daylight Time

Image
Article thumbnail News Release

Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian

Global Markets News

Summit Therapeutics (NASDAQ: SMMT) recently captured headlines with the release of its Phase 3 data for ivonescimab, a targeted NSCLC therapy that has generated substantial buzz. The results from its trial conducted in China showed a dramatic 49% reduction in the risk of disease progression or death compared to Merck’s Keytruda, signaling a potentially disruptive force in NSCLC treatment. However, the news wasn’t without its concerns—since the trial data originates from China, there are questions about its applicability to broader, global populations. As noted by BMO Capital Markets’ Evan Seigerman: “Results may or may not be generalizable beyond the China-focused patient population initially assessed.” Despite this, Summit’s valuation has risen by over 100%, now approximating $19 billion. With such a high valuation, the company could see limited room for further significant gains, leading many in the industry to explore other emerging opportunities in precision oncology. Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising initial results and could see similar success in the future if they were to report positive results. These emerging players are worth watching for those interested in following precision oncology drug candidates and pipelines. Among them are precision oncology innovators such as Silexion Therapeutics, Nuvectis Pharma, and Scorpion Therapeutics, which we discuss below. Silexion Therapeutics: Disrupting the KRAS-Driven Cancer Space Silexion Therapeutics (NASDAQ: SLXN) is another under-the-radar player in the precision oncology space, with a focus on KRAS-driven cancers—a notoriously difficult target in oncology. While current small-molecule KRAS inhibitors are making progress, they are often limited to specific mutations, such as KRAS G12C, which accounts for a small percentage of cancers. Silexion’s RNA interference (RNAi) approach offers a broader solution, targeting a wider spectrum of KRAS mutations, particularly in pancreatic cancer, one of the deadliest and most treatment-resistant cancers. At the heart of Silexion’s approach is its LODER™ platform, which delivers siRNA directly to the tumor site, silencing KRAS mutations at the genetic level. This localized delivery not only increases efficacy by concentrating the treatment in the tumor, but it also reduces systemic side effects. Silexion’s next-generation candidate, SIL-204, is an optimized siRNA formulation designed to target pan-KRAS G12x mutations, positioning it to treat a broader range of KRAS-driven cancers beyond pancreatic cancer, such as lung and colorectal cancers. In Phase 2 trials for locally advanced pancreatic cancer, Silexion's LODER™ platform showed a 9.3-month improvement in overall survival when combined with standard chemotherapy. Additionally, the objective response rate (ORR) increased from 20% with chemotherapy alone to 55% with the combination, and in some cases, tumors that were initially non-resectable became operable after treatment with LODER™. These results are especially encouraging given the limited options available for pancreatic cancer patients. SIL-204, is expected to enter Phase 2/3 clinical trials in 2025-2026. What makes Silexion particularly intriguing is its current market valuation. Valued at aproximatly just ~$9 million following its SPAC merger, the company’s valuation could be perceived as low when compared to some of its peers, especially given its innovative technology and promising clinical achievements. Some have wondered whether this low valuation has more to do with dynamics post-SPAC companies. If Silexion can report positive results in its later-stage trials, the company’s outlook could dramatically improve, reflecting the potential of its RNAi-based platform. Like NXP900, SIL-204 could potentially have vast applications across multiple KRAS-driven cancer types, making Silexion a company to watch closely as it advances through clinical development. Nuvectis Pharma: Targeting NSCLC and Beyond by Inhibiting SRC/YES1 Kinases Nuvectis Pharma (NASDAQ: NVCT) has been quietly making strides in the precision oncology sector, developing innovative therapies aimed at overcoming treatment resistance in hard-to-treat cancers. Its lead candidate, NXP900, targets NSCLC by inhibiting the SRC/YES1 kinases, which play critical roles in cancer cell survival and resistance to current therapies. This approach positions NXP900 as a potential game-changer in the treatment of NSCLC, particularly in patients who have developed resistance to EGFR and ALK inhibitors, such as AstraZeneca’s Tagrisso and Novartis’ Alecensa. NXP900 is still in the early stages of clinical development, currently undergoing Phase 1 trials. However, preclinical studies have already shown that it has strong anti-tumor activity in resistant NSCLC models. Even more promising is its potential application beyond NSCLC. Like Summit's ivonescimab, NXP900 focuses on resistance, but it also has broader applications due to its ability to target multiple cancer types driven by SRC/YES1 pathways. This versatility makes it a promising asset not just for NSCLC but also for other difficult-to-treat cancers like squamous cell carcinomas. In addition to NXP900, Nuvectis is advancing NXP800, another precision oncology candidate that is further along in the clinical development process. NXP800 is currently in Phase 1b trials, targeting ARID1a-mutated cancers such as ovarian and endometrial cancers. The early clinical data for NXP800 is promising, showing positive responses in patients with platinum-resistant ovarian cancer. With two strong candidates in the pipeline, Nuvectis is positioning itself as a formidable player in the precision oncology landscape. As Summit’s ivonescimab continues to gain attention, Nuvectis’ earlier-stage NXP900, with its NSCLC focus and beyond, could see similar success in the future if clinical results continue to trend positively. Scorpion Therapeutics: Pioneering Mutant-Selective Therapies Scorpion Therapeutics is redefining the frontier of precision oncology with its focus on delivering highly selective small molecules targeting validated and previously undruggable cancer mutations. Its lead candidate, STX-478, is a mutant-selective, allosteric PI3Kα inhibitor currently in Phase 1/2 trials for advanced solid tumors. Early data presented at the ESMO Congress 2024 highlighted its potential, with STX-478 demonstrating a 23% overall response rate in breast cancer and a 21% response rate across all tumor types, positioning it as a potentially best-in-class PI3Kα inhibitor. STX-478 is notable for its ability to spare wild-type PI3Kα activity in normal tissues, avoiding the toxicities seen with previous PI3Kα inhibitors, such as hyperglycemia and rash. Tumor reductions were seen in 72% of patients treated with STX-478 as a monotherapy, with circulating tumor DNA levels dropping in 86% of patients. This mutant-selective precision could help overcome the limitations of existing PI3Kα inhibitors, which have struggled with dose-limiting toxicities. In July 2024, Scorpion raised $150 million in a Series C financing round, co-led by Frazier Life Sciences and Lightspeed Venture Partners. The additional funding will support the advancement of STX-478 and other pipeline assets, positioning Scorpion for further clinical success. Scorpion’s pipeline includes a broad range of wholly-owned compounds that target both validated and novel cancer targets, positioning the company for future expansion into larger patient populations. As STX-478 progresses through clinical development, Scorpion is poised to become a significant player in the precision oncology space, making it another company worth watching closely. Optimistic Outlook for Precision Oncology The precision oncology space is experiencing a golden era of innovation, with companies like Summit Therapeutics, Nuvectis Pharma, Silexion Therapeutics, and Scorpion Therapeutics leading the charge. As the focus shifts towards targeted therapies that address resistance mechanisms, the market is increasingly favoring companies with novel approaches and broad applications. Summit’s meteoric rise has shown that there is tremendous potential for companies that can demonstrate efficacy in overcoming cancer resistance. While Summit has already captured much of the current attention, companies like Nuvectis, Silexion, and Scorpion, with their earlier-stage pipelines, offer exciting opportunities for the industry to keep a close eye on. As these companies continue to report clinical data and advance through trials, the potential for breakthroughs in treating some of the most difficult cancers grows stronger. With targeted therapies offering the possibility of overcoming resistance without the need for chemotherapy, the future of cancer treatment looks brighter than ever. For those in the oncology space, keeping a close eye on emerging players like Nuvectis, Silexion, and Scorpion could lead to transformative developments as the field of precision oncology continues to evolve. * * * This update may include speculative forward looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. the BioTech and Pharma industries are volatile and risky and readers are advised to seek out preffesional advice in the relevent feilds from licensed profesionals. This update is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. [ https://justpaste.it/ch2qt/pdf ]. Global Markets News Network is a commercial digital brand compensated to provide coverage of news and developments related to innovative companies as detailed in the full documentation and it is thus subject to conflicts of interest. Contact Details News Coverage ronald@futuremarketsresearch.com

September 19, 2024 07:45 AM Eastern Daylight Time

1 23456 ... 347